4TO.F MAINZ BIOMED B.V. EO 1
- Market cap
- EUR 17.4M
- P/E
- -
- P/B
- 1.72x
- ROE
- -158.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4TO.F undervalued?
Graham numberThe Graham number of MAINZ BIOMED B.V. EO 1 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MAINZ BIOMED B.V. EO 1 fundamental analysis
No fundamental analysis for MAINZ BIOMED B.V. EO 1 yet.
MAINZ BIOMED B.V. EO 1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MAINZ BIOMED B.V. EO 1
Quantum Cyber N.V. operates as a technology company focused on cybersecurity and quantum computing solutions. The company pursues acquisitions and partnerships in areas including post-quantum cryptography, zero-trust architecture, and national security technologies. It also develops platforms that integrate artificial intelligence (AI) and quantum computing technologies for autonomous control systems used in unmanned aerial, ground, and underwater vehicles, including drones,…
Full company profileMAINZ BIOMED B.V. EO 1 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MAINZ BIOMED B.V. EO 1 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 577K | 530K | 895K | 894K | 537K | 0.00 |
| Gross Profit | 178K | 182K | 510K | 575K | 390K | - |
| Operating Income | -9.72M | -26.4M | -26.6M | -18.3M | -12.9M | -16.2M |
| EBITDA | - | -25.7M | -24.9M | -20.0M | -15.2M | -25.0M |
| Net Income | -11.7M | -26.4M | -26.3M | -21.6M | -16.2M | -32.2M |
| EPS | -39 | -72 | -50 | -9.31 | -1.79 | -1.41 |
| Balance Sheet | ||||||
| Total Assets | 10.0M | 20.2M | 15.4M | 13.2M | 5.33M | 23.4M |
| Total Liabilities | 3.68M | 6.14M | 12.2M | 7.19M | 4.69M | 3.00M |
| Shareholders' Equity | 6.36M | 14.1M | 3.25M | 6.05M | 642K | 20.4M |
| Cash & Short-term Investments | 8.73M | 17.1M | 7.07M | 6.24M | 889K | 13.4M |
| Cash Flow | ||||||
| Operating Cash Flow | -3.22M | -14.8M | -21.9M | -17.1M | -11.0M | -19.8M |
| Capital Expenditure | 16.7K | 658K | 1.90M | 255K | 1.05M | 1.97M |
| Free Cash Flow | -3.24M | -15.4M | -23.8M | -17.3M | -12.0M | -21.8M |
| Ratios | ||||||
| ROE | -183.8% | -187.2% | -809.3% | -357.2% | -2,526.6% | -158.1% |
| ROA | -116.4% | -130.4% | -170.7% | -163.2% | -304.3% | -137.8% |
| Net Profit Margin | -2,024.8% | -4,979.9% | -2,936.5% | -2,416.0% | -3,018.3% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MAINZ BIOMED B.V. EO 1 dividends
MAINZ BIOMED B.V. EO 1 has not paid dividends in the last 5 fiscal years.
Last stock split: 1:40 on Dec 3, 2024.
Who owns MAINZ BIOMED B.V. EO 1
- Insiders 67.97%
- Institutions 0.28%
- Public & others 31.75%
- Shares outstanding 87.2M
- Free float 24.3M
MAINZ BIOMED B.V. EO 1 company profile
- Company name
- MAINZ BIOMED B.V. EO 1
- Ticker
- 4TO.F
- ISIN
- NL0015000LC2
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Fiscal year end
- December
- Address
- Robert Koch Strasse 50, Mainz, Germany, 55129
- Phone
- 49 6131 554 2860
- Website
- quantum-cyber.ai
About MAINZ BIOMED B.V. EO 1
Quantum Cyber N.V. operates as a technology company focused on cybersecurity and quantum computing solutions. The company pursues acquisitions and partnerships in areas including post-quantum cryptography, zero-trust architecture, and national security technologies. It also develops platforms that integrate artificial intelligence (AI) and quantum computing technologies for autonomous control systems used in unmanned aerial, ground, and underwater vehicles, including drones, self-driving vehicles, and robotic fleets. Quantum Cyber N.V. was formerly known as Mainz Biomed N.V. and changed its name to Quantum Cyber N.V. in April 2026. The company is headquartered in Mainz, Germany.
MAINZ BIOMED B.V. EO 1 management
5- Mr. David Elliot LazarCEO & Director · born 1991
- Dr. Christopher Von Toerne P.M.P., Ph.D.Chief Operating Officer · born 1972
- Mr. Dennis SchnurHead of U.S. Sales
- Mr. Stefan ErlachHead of Human Resources
- Mr. Tzvi LevHead of Sales - Middle East